Skip to main content
Erschienen in:

01.03.2015 | Leitthema

Intensivierte Früherkennung bei Frauen mit genetischer Brustkrebsdisposition

verfasst von: Prof. Dr. I. Schreer

Erschienen in: Die Onkologie | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die für eine Brustkrebsfrüherkennung bei Frauen mit durchschnittlichem Risiko eingesetzten bildgebenden Methoden (Mammographie, Sonographie) in Ergänzung zur klinischen Untersuchung sind für Mutationsträgerinnen und Frauen mit hoher familiärer Brust- und Eierstockkrebsbelastung unzureichend. Die hohe Krebsinzidenz, das deutlich frühere Erkrankungsalter und das damit häufig einhergehende röntgendichte Drüsengewebe erfordern eine zeitlich und methodisch effektivere Strategie.

Schlussfolgerung

Führende bildgebende Methode ist daher bei BRCA1/2-Mutationsträgerinnen ab dem 25. bis zum 70. Lebensjahr die KM-MRT in jährlichem Intervall. Die Mammographie hat für BRCA-Trägerinnen nachgeordnete Bedeutung, während die Sonographie im halbjährlichen Intervall Vorteile verspricht. Frauen mit familiär gehäuftem Brustkrebs (lebenslanges Risiko > 30 %) werden jährlich ab dem 30. Lebensjahr mit klinischer Untersuchung, digitaler Mammographie (ab dem 40. Lebensjahr) und Sonographie sowie MRT bis zum 50. Lebensjahr untersucht und in der Folge weiter im Rahmen der Regelversorgung. Bezüglich des Überlebens liegen noch keine ausreichend langen Verläufe vor. Die mit einem jährlichen MRT-Angebot häufig in frühen Stadien detektierten Tumoren stimmen allerdings hoffnungsvoll.
Literatur
1.
Zurück zum Zitat Mavaddat N, Poeck S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812–822CrossRefPubMed Mavaddat N, Poeck S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812–822CrossRefPubMed
2.
Zurück zum Zitat Meindl A, Ditsch N, Kast K et al (2011) Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 108:232–330 Meindl A, Ditsch N, Kast K et al (2011) Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 108:232–330
3.
Zurück zum Zitat Baker JL, Schwab RB, Wallace AM, Madlensky L (2015) Breast cancer in a RAD51D mutation carrier: case report and review of the literature. Clin Breast Cancer 15(1):e71–e75CrossRefPubMed Baker JL, Schwab RB, Wallace AM, Madlensky L (2015) Breast cancer in a RAD51D mutation carrier: case report and review of the literature. Clin Breast Cancer 15(1):e71–e75CrossRefPubMed
4.
Zurück zum Zitat Allen SD, Wallis MB, Cooke R, Swerdlow AJ (2014) Radiologic features of breast cancer after mantle radiation therapy for Hodgkin disease: a study of 230 cases. Radiology 272(2):73–78CrossRefPubMed Allen SD, Wallis MB, Cooke R, Swerdlow AJ (2014) Radiologic features of breast cancer after mantle radiation therapy for Hodgkin disease: a study of 230 cases. Radiology 272(2):73–78CrossRefPubMed
5.
Zurück zum Zitat Schellong G, Riepenhausen M, Ehlert K et al (2014) Breast cancer in young women after treatment for Hodgkin’s disease during childhood or adolescence: an observational study with up to 33-year follow-up. Dtsch Ärzteblatt Int 111(1–2):3–9 Schellong G, Riepenhausen M, Ehlert K et al (2014) Breast cancer in young women after treatment for Hodgkin’s disease during childhood or adolescence: an observational study with up to 33-year follow-up. Dtsch Ärzteblatt Int 111(1–2):3–9
6.
Zurück zum Zitat Miller AB, To T, Baines CJ, Wall C (2000) Canadian National Breast Screening Study-2: 13 – year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst 92(18)1490–1499 Miller AB, To T, Baines CJ, Wall C (2000) Canadian National Breast Screening Study-2: 13 – year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst 92(18)1490–1499
7.
Zurück zum Zitat Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437CrossRefPubMed Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437CrossRefPubMed
8.
Zurück zum Zitat Rijnsburger AJ, Obdeijn IM, Kaas R et al (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28:5265–5273CrossRefPubMed Rijnsburger AJ, Obdeijn IM, Kaas R et al (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28:5265–5273CrossRefPubMed
9.
Zurück zum Zitat Sardanelli F, Podo F, Santoro F et al (2011) Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography and contrast-enhanced magnetic resonance (The High Breast Cancer Risk Italian 1 study. Final results. Invest Radiol 57(2):75–89 Sardanelli F, Podo F, Santoro F et al (2011) Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography and contrast-enhanced magnetic resonance (The High Breast Cancer Risk Italian 1 study. Final results. Invest Radiol 57(2):75–89
10.
Zurück zum Zitat Maurice M, Evans DG, Affen J et al (2012) Surveillance of women at increased risk of breast cancer and clinical breast evaluation: further evidence of benefit. Int J Cancer 131(2):417–425CrossRefPubMed Maurice M, Evans DG, Affen J et al (2012) Surveillance of women at increased risk of breast cancer and clinical breast evaluation: further evidence of benefit. Int J Cancer 131(2):417–425CrossRefPubMed
11.
Zurück zum Zitat Bosse K, Graser M, Großmann A et al (2014) Supplemental screening ultrasound increases breast cancer detection in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 289:663–670CrossRefPubMed Bosse K, Graser M, Großmann A et al (2014) Supplemental screening ultrasound increases breast cancer detection in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 289:663–670CrossRefPubMed
12.
Zurück zum Zitat Mesurolle B, Kadoch L, El-Koury M et al (2007) Sonographic features of breast carcinoma presenting as masses in BRCA gene mutation carriers. J Ultrasound Med 26:817–824PubMed Mesurolle B, Kadoch L, El-Koury M et al (2007) Sonographic features of breast carcinoma presenting as masses in BRCA gene mutation carriers. J Ultrasound Med 26:817–824PubMed
13.
Zurück zum Zitat Riedl CC, Ponhold L, Flöry D et al (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 13(20):6144–6152CrossRefPubMed Riedl CC, Ponhold L, Flöry D et al (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 13(20):6144–6152CrossRefPubMed
14.
Zurück zum Zitat Kuhl C, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28:1450–1457CrossRefPubMed Kuhl C, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28:1450–1457CrossRefPubMed
15.
Zurück zum Zitat Mavaddat N, Barrowdale D, Andrulla I et al (2015) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Cancer Epidemiol Biomarkers 21(1):134–147CrossRef Mavaddat N, Barrowdale D, Andrulla I et al (2015) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Cancer Epidemiol Biomarkers 21(1):134–147CrossRef
16.
Zurück zum Zitat Lakhani SR, Vijer MJ van de, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers Estrogen Receptor, Progesterone Receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318CrossRefPubMed Lakhani SR, Vijer MJ van de, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers Estrogen Receptor, Progesterone Receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318CrossRefPubMed
17.
Zurück zum Zitat Bane A, Pinnaduwage SC, Bull SB et al (2009) Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 117:183–191CrossRefPubMedCentralPubMed Bane A, Pinnaduwage SC, Bull SB et al (2009) Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 117:183–191CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Hellquist BN, Duffy SW, Abdsaleh S et al (2011) Effectiveness of population-based service screening with mammography for women ages 40–49 years: evaluation of the Swedish Mammography Screening In Young Women (SCRY) cohort. Cancer 117(4):714–722CrossRefPubMed Hellquist BN, Duffy SW, Abdsaleh S et al (2011) Effectiveness of population-based service screening with mammography for women ages 40–49 years: evaluation of the Swedish Mammography Screening In Young Women (SCRY) cohort. Cancer 117(4):714–722CrossRefPubMed
19.
Zurück zum Zitat Moss SM, Cuckle H, Evans J et al (2006) Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years‘ follow-up: a randomized controlled trial. Lancet 368(9552):2053–2060CrossRefPubMed Moss SM, Cuckle H, Evans J et al (2006) Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years‘ follow-up: a randomized controlled trial. Lancet 368(9552):2053–2060CrossRefPubMed
20.
Zurück zum Zitat Marmot MG, Altman DG, Cameron DA et al (2012) The benefits and harms for breast cancer: an independent review. Lancet 380:1778–1785CrossRef Marmot MG, Altman DG, Cameron DA et al (2012) The benefits and harms for breast cancer: an independent review. Lancet 380:1778–1785CrossRef
21.
Zurück zum Zitat FH01 collaborative teams (2010) Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumor characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 11:1127–1134 FH01 collaborative teams (2010) Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumor characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 11:1127–1134
22.
Zurück zum Zitat Malmgren JA, Parikh J, Atwood MK, Kaplan HG (2012) Impact of mammography detection on the course of breast cancer in women aged 40–49 years. Radiology 262(3):787CrossRef Malmgren JA, Parikh J, Atwood MK, Kaplan HG (2012) Impact of mammography detection on the course of breast cancer in women aged 40–49 years. Radiology 262(3):787CrossRef
23.
Zurück zum Zitat Sprague BL, Gangnon RE, Burt V et al (2014) Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 106(10). doi:10.1093/jnci/dju255 Sprague BL, Gangnon RE, Burt V et al (2014) Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 106(10). doi:10.1093/jnci/dju255
24.
Zurück zum Zitat Fernandez-Navarro P, Gonzales-Neira A, Pita G et al (2014) Genome wide association study identifies a novel putative mammography density locus at 1q12-q21. Int J Cancer. doi:10.1002/ijc.29299 Fernandez-Navarro P, Gonzales-Neira A, Pita G et al (2014) Genome wide association study identifies a novel putative mammography density locus at 1q12-q21. Int J Cancer. doi:10.1002/ijc.29299
25.
Zurück zum Zitat Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast cancer screening. N Engl J Med 353:1773–1783CrossRefPubMed Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast cancer screening. N Engl J Med 353:1773–1783CrossRefPubMed
26.
Zurück zum Zitat Hagen AI, Kvistad KA, Maehle L et al (2007) Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367–274CrossRefPubMed Hagen AI, Kvistad KA, Maehle L et al (2007) Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367–274CrossRefPubMed
27.
Zurück zum Zitat Yaffe MJ, Mainprize JG (2011) Risk of radiation-induced breast cancer from mammographic screening. Radiology 258:98–105CrossRefPubMed Yaffe MJ, Mainprize JG (2011) Risk of radiation-induced breast cancer from mammographic screening. Radiology 258:98–105CrossRefPubMed
28.
Zurück zum Zitat Heijnsdijk EAM, Warner E, Gilbert FJ et al (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carries and effects of MRI Screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21:1458–1468CrossRefPubMed Heijnsdijk EAM, Warner E, Gilbert FJ et al (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carries and effects of MRI Screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21:1458–1468CrossRefPubMed
29.
Zurück zum Zitat Jansen-van der Weide MC, Greuter MJ, Jansen L et al (2010) Exposure to tow-dose radiation and the risk of breast cancer among woman with a familial or genetic predisposition: a metaanalysis. Eur Radiol 20:2547–2556CrossRef Jansen-van der Weide MC, Greuter MJ, Jansen L et al (2010) Exposure to tow-dose radiation and the risk of breast cancer among woman with a familial or genetic predisposition: a metaanalysis. Eur Radiol 20:2547–2556CrossRef
30.
Zurück zum Zitat Pijpe A, Andrieu N, Easton DF et al (2012) Exposure the diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 345:e5660CrossRefPubMedCentralPubMed Pijpe A, Andrieu N, Easton DF et al (2012) Exposure the diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 345:e5660CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Giannakas V, Lubinski J, Gronwald J et al (2014) Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Res Treat 147:113–118CrossRef Giannakas V, Lubinski J, Gronwald J et al (2014) Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Res Treat 147:113–118CrossRef
32.
Zurück zum Zitat Skaane P, Bandos AI, Eben EB et al (2014) Two-view breast tomosynthesis screening with specially reconstructed projection images; comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3):655–663CrossRefPubMed Skaane P, Bandos AI, Eben EB et al (2014) Two-view breast tomosynthesis screening with specially reconstructed projection images; comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3):655–663CrossRefPubMed
33.
Zurück zum Zitat Gareth ED, Nisha K, Yit L et al (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145(3):663–672CrossRefPubMed Gareth ED, Nisha K, Yit L et al (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145(3):663–672CrossRefPubMed
34.
Zurück zum Zitat Chiarelli AM, Prummel MV, Muradali D et al (2014) Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 32:2224–2230CrossRefPubMed Chiarelli AM, Prummel MV, Muradali D et al (2014) Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 32:2224–2230CrossRefPubMed
35.
Zurück zum Zitat Saadatmad S, Vos JR, Honning MJ et al (2014). Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. Int J Cancer 135:2940–2949CrossRef Saadatmad S, Vos JR, Honning MJ et al (2014). Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. Int J Cancer 135:2940–2949CrossRef
36.
Zurück zum Zitat Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222–231CrossRefPubMedCentralPubMed Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222–231CrossRefPubMedCentralPubMed
37.
Zurück zum Zitat Chai X, Friebel TM, Singer CF et al (2014) Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carries. Breast Cancer Res Treat 148:397–406CrossRefPubMed Chai X, Friebel TM, Singer CF et al (2014) Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carries. Breast Cancer Res Treat 148:397–406CrossRefPubMed
38.
Zurück zum Zitat Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A et al (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24:2029–2035CrossRefPubMed Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A et al (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24:2029–2035CrossRefPubMed
39.
Zurück zum Zitat Kirova MY, Savignoni A, Sigal-Zafrani B et al (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120:119–126CrossRefPubMed Kirova MY, Savignoni A, Sigal-Zafrani B et al (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120:119–126CrossRefPubMed
40.
Zurück zum Zitat Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 144:443–455 (2007;13(20):6144–6152) Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 144:443–455 (2007;13(20):6144–6152)
41.
Zurück zum Zitat Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutations carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325CrossRefPubMed Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutations carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325CrossRefPubMed
42.
Zurück zum Zitat Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769–1778CrossRefPubMed Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769–1778CrossRefPubMed
43.
Zurück zum Zitat Passaperuma K, Warner E, Causer PA et al (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 127:24–30CrossRef Passaperuma K, Warner E, Causer PA et al (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 127:24–30CrossRef
Metadaten
Titel
Intensivierte Früherkennung bei Frauen mit genetischer Brustkrebsdisposition
verfasst von
Prof. Dr. I. Schreer
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 3/2015
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-014-2838-4

Weitere Artikel der Ausgabe 3/2015

Der Onkologe 3/2015 Zur Ausgabe

CME Zertifizierte Fortbildung

Fehl- und Mangelernährung in der Onkologie

Journal Club

AMAROS-Studie

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.